Valeant Pharmaceuticals celebrates the manufacturing of four billion bottles of eye care products at Bausch + Lomb's Greenville Solutions Plant
![](/46/pdcnewsitem/03/75/58/valeant.jpg)
Commemorative bottles specially labelled to denote the batch containing the four billionth bottle were produced for the occasion.
Valeant Pharmaceuticals International has announced that the company celebrated the production of the four billionth bottle of eye care products manufactured at Bausch + Lomb's Greenville Solutions Plant, with Valeant Chairman and CEO J. Michael Pearson joining elected officials, employees, and local business leaders on a tour of the South Carolina facility. Commemorative bottles specially labelled to denote the batch containing the four billionth bottle were produced for the occasion.
The Bausch + Lomb solutions plant has been a staple of the Greater Greenville community for more than 30 years since opening in 1983. The plant employs a workforce of more than 500 employees who help to manufacture more than 30 essential medical products, which are then sent to a nearby shipping facility to be packaged and transported around the world. Among the top global Valeant brands manufactured at the Greenville facility include Biotrue multi-purpose solution, ReNu Solutions, and Boston solutions for gas permeable contact lenses. Many of the Greenville Solutions Plant's employees have worked at the site for more than 10 years.
In addition, Valeant and Bausch + Lomb executives announced a new, state-of-the-art, integrated line investment of approximately $25 million. The expansion, coupled with a previously approved solutions-making investment, will add 40 million units of capacity — an overall increase of more than 20%. More than 30 new jobs will be created from the increase in capacity, with an expected $7 million spent on local construction and engineering firms. Valeant is also committing to new investments of approximately $90 million over the next two years, and approximately $150 million over the next five years, which is expected to result in 150 to 200 new jobs in the next 5 years.
"Reaching this incredible milestone at Bausch + Lomb's Greenville Solutions Plant demonstrates the enormous impact that the facility has had across the globe," said Pearson. "Whether it's one of the hundreds of employees creating our top-of-the-line products, or a consumer who has bought one of our four billion bottles manufactured at this facility for his or her lens care needs, the work that is done here is essential to peoples' lives. We are incredibly proud of the employees in Greenville, who reflect the very best of Valeant Pharmaceuticals."
"Congratulations to the Bausch + Lomb Greenville Solutions Plant on your four billionth bottle, and to 32 years of bringing manufacturing jobs to the Upstate," said Senator Lindsey Graham. "South Carolinians are grateful to have such an essential business in our state, and we look forward to many more years of success and positive community impact."
"Longstanding businesses in our community have provided valuable contributions to our thriving workforce," said Senator Tim Scott. "Being able to celebrate major production milestones underscores the dedication of these businesses in our state, and reinforces South Carolina's role as the center of our nation's manufacturing renaissance."
"Thank you to the Bausch + Lomb Greenville Solutions Plant for the invitation to celebrate the production of its four billionth bottle," said Representative Trey Gowdy. "For over 30 years, the Greenville Bausch + Lomb facility has continued to manufacture and export products worldwide, supporting hundreds of jobs in the Upstate. Congratulations on this achievement."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance